

Editorial

Effect of Percutaneous Coronary Intervention on Quality of Life: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions

James C. Blankenship,^{1*} MD, FSCAI, J. Jeffrey Marshall,² MD, FSCAI, Duane S. Pinto,³ MD, MPH, FSCAI, Richard A. Lange,⁴ MD, MBA, FSCAI, Eric R. Bates,⁵ MD, FSCAI, Elizabeth M. Holper,⁶ MD, MPH, FSCAI, Cindy L. Grines,⁷ MD, FSCAI, and Charles E. Chambers,⁸ MD, FSCAI

Percutaneous coronary intervention (PCI) decreases ischemic complications of acute coronary syndromes. The benefits of PCI in stable ischemic heart disease (SIHD) depend on its effect on quality of life (QoL), including angina, physical activity, and emotional well-being. PCI decreases angina and the need for anti-anginal medications, and increases exercise capacity and QoL, compared with baseline status and compared with medical therapy without PCI. These benefits are greater when QoL is markedly impaired by severe angina before the procedure. When considering treatment options for symptomatic SIHD, physicians should consider and provide objective data regarding QoL effects for each treatment strategy. QoL outcomes should be considered in clinical trials, appropriate use criteria, practice guidelines, and reimbursement policies for PCI. © 2012 Wiley Periodicals, Inc.

Key words: stenting; percutaneous coronary intervention; quality of life; angina

INTRODUCTION

Patients have been treated successfully with percutaneous coronary intervention (PCI) for over 30 years. PCI decreases mortality in ST-elevation myocardial infarction (STEMI) [1–4] and reduces recurrent ischemic events (although not mortality) in patients with non-ST elevation acute coronary syndromes (NSTEMI-ACS) [5,6]. The benefit of PCI in STEMI and NSTEMI-ACS is accepted and a recent study concluded that 99% of PCI procedures performed for these clinical situations were appropriate [7]. However, the value of PCI in patients with stable ischemic heart disease (SIHD) has recently been questioned for several reasons. First, studies comparing PCI with medical therapy in patients with SIHD [8–11] demonstrate that PCI is similar but not superior to optimal medical therapy in preventing death or myocardial infarction (MI). Second, recent studies comparing PCI with medical therapy [8–11] demonstrated smaller than expected differences in angina relief, especially over several years of follow-up. Finally, exaggeration or overestimation of the alleged benefits of PCI in SIHD patients [7,12–17] may contribute to the recently reported inappropriate use of PCI [7,17].

Since PCI does not decrease the incidence of MI or death in SIHD patients, its major potential benefit may be in improving quality of life (QoL), which is worse

¹Geisinger Medical Center, Danville, Pennsylvania

²Northeast Georgia Heart Center, Gainesville, Georgia

³Beth Israel Deaconess Medical Center, Boston, Massachusetts

⁴University of Texas Health Science Center at San Antonio, San Antonio, Texas

⁵University of Michigan Hospitals and Health Centers, Ann Arbor, Michigan

⁶Medical City Hospital, Dallas, Texas

⁷Detroit Medical Center Cardiovascular Institute, Detroit, Michigan

⁸Hershey Medical Center, Hershey, Pennsylvania

Conflict of interest: Nothing to report.

*Correspondence to: James C. Blankenship, MD, FSCAI, Department of Cardiology, 27-75, Geisinger Medical Center, Danville, PA 17822. E-mail: jblankenship@geisinger.edu

Received 17 January 2012; Revision accepted 12 February 2012

DOI 10.1002/ccd.24376

Published online in Wiley Online Library (wileyonlinelibrary.com)

2 Blankenship et al.

TABLE I. Guidelines for PCI for Control of Symptoms

2011 ACC/AHA/SCAI PCI Guidelines to Improve Symptoms [19]

CLASS I

1. PCI to improve symptoms is beneficial in patients with 1 or more significant ($\geq 70\%$ diameter) coronary artery stenoses amenable to revascularization and unacceptable angina despite guideline-directed medical therapy (GDMT). (*Level of Evidence: A*)

CLASS IIa

1. PCI to improve symptoms is reasonable in patients with 1 or more significant ($\geq 70\%$ diameter) coronary artery stenoses and unacceptable angina for whom GDMT cannot be implemented because of medication contraindications, adverse effects, or patient preferences. (*Level of Evidence: C*)

2. PCI to improve symptoms is reasonable in patients with previous CABG, 1 or more significant ($\geq 70\%$ diameter) coronary artery stenoses associated with ischemia, and unacceptable angina despite GDMT. (*Level of Evidence: C*)

CLASS III: HARM

1. PCI to improve symptoms should not be performed in patients who do not meet anatomic ($\geq 50\%$ left main or greater than or equal to $\geq 70\%$ non-left main stenosis) or physiological (e.g., abnormal fractional flow reserve) criteria for revascularization. (*Level of Evidence C*)

2010 European Society of Cardiology Guidelines on Myocardial Revascularization to Improve Symptoms [20]

CLASS I

1. Any stenosis $>50\%$ with limiting angina or angina equivalent, unresponsive to optimal medical therapy (OMT). (*Level of Evidence: A*)

CLASS IIa

1. Dyspnea/CHF and $>10\%$ left ventricular ischemia/viability supplied by $>50\%$ stenotic artery. (*Level of Evidence: B*)

CLASS III

1. No limiting symptoms with OMT. (*Level of Evidence C*)

“Guideline-directed medical therapy (GDMT) represents optimal medical therapy as defined by ACCF/AHA guideline recommended therapies (primarily Class I).”
 “Optimal medical therapy (OMT) includes intensive lifestyle and pharmacological management.”

in patients with SIHD compared with those without SIHD [18]. The benefits of PCI in improving QoL have been extensively studied and have influenced T1 guidelines for performance of PCI (Table I), where QoL is clearly articulated as a primary goal and benefit of treatment [19,20]. The purpose of this article is to review the relevant literature describing the effects of PCI on QoL and recommend how QoL should be used in guiding therapeutic decisions.

METHODS OF ASSESSING QoL

Outcome metrics such as severity of angina, anti-anginal medication use, exercise duration, and recurrent angina after initial treatment have been used to assess QoL [21]. However, these outcomes are subject to confounding factors such as comorbid illnesses, physician practice patterns, and access to health care. For example, trials of stents often include angiographic follow-up in which target vessel revascularization may be performed in the absence of symptoms or QoL impairment. Conventional outcomes such as recurrent MI or angina relief may not accurately weight or quantify changes in QoL because they fail to take into account the patient’s perception of physical, emotional, social,

and psychological well-being. For example, a strategy based on medical therapy may relieve angina completely but at the cost of decreased QoL due to drug side effects or avoidance of valued activities [22]. Consequently, instruments that more comprehensively measure QoL by assessing the physical, psychological, social, and functional domains of a patient’s life have been developed (Table II) [23]. These QoL measures are essential for the various medical specialties that focus on improving QoL as part of chronic disease management. In other medical specialties, studies have demonstrated that procedures can improve QoL [24–27]. Post-procedural QoL is influenced by many factors [28–31] including late procedural complications which lead to adverse clinical events (e.g., restenosis, recurrent angina, and hospitalization) [32,33].

Utilities are an additional method for assessing patients’ perspectives of their health status. These scales are determined by a variety of mechanisms (e.g., time trade-off, standard gamble or questionnaires mapped to societal-based utilities). Whereas it is impractical to measure utilities for every disease state, when available they can be integrated with survival to generate quality-adjusted life years (QALYs) that are important for economic analyses [49–51]. The QALY

T2

TABLE II. Instruments Commonly Used to Evaluate Health Status and Quality of Life (QoL) in Patients With Stable Ischemic Heart Disease

Name of instrument	Description
Disease-specific quality of life/health status instruments	
Ferrans and Powers Quality of Life Index [34]	Measures both satisfaction and importance of various aspects of life. Importance ratings are used to weight the satisfaction response in four dimensions: health and functioning, socioeconomic, psychological/spiritual, and family
McMaster Health Index Questionnaire [35]	QoL measures based on physical, social and emotional functions. Measures are based on respondent's feelings and thoughts, but does not relate these to illness.
Medical Outcomes Study Short-Form 36 (SF-36) [36]	Consists of eight scaled scores, which are the weighted sums of the questions in their section measuring vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning and mental health. RAND-36 includes same items but is scored differently.
Short-Form 12 [37,38]	Shortened version of SF-36 and has been found to correlate well with the SF-36 summary scores in various disease states including angina
Nottingham Health Profile [39]	Evaluates six dimensions of health subjectively including: physical mobility, pain, social isolation, emotional reactions, energy, and sleep as well as statements about seven areas of life that are most affected by health status. Most useful for chronic and pronounced symptoms and for detecting treatment effects.
Psychological Well-Being Index [39,40]	Composed of six dimensions divided into 22 items: anxiety, depression, positive mood, vitality or energy, self-control repertoires, overall health-related perceptions of illness. Suitable for evaluating the impact of symptoms on well-being and applicable for both healthy and patient populations.
Quality of Well-Being Scale [41]	Based on the societal preferences associated with a person's level of functioning at specific point in time. Averages values across three ratings of functioning: mobility, physical activity, social activity, and across one rating of symptomatic complaints that might inhibit function.
Sickness Impact Profile (SIP) [42]	Everyday activities in 12 categories (sleep and rest, emotional behavior, body care and movement, home management, mobility, social interaction, ambulation, alertness behavior, communication, work, recreation and pastimes, and eating) are measured. Scoring can be done at the level of categories and dimensions as well as at the total SIP level.
Swedish Health-Related Quality of Life Survey [43]	Consists of 61 items that form 11 multi-item scales assessing aspects of physical, mental, social and general health
Duke Activity Status Index (DASI) [44]	A 12-item scale measuring functional status. Asks questions about common activities and correlates with peak oxygen consumption.
Disease-specific quality of life/health status instruments	
MacNew Instrument (QoL after Myocardial Infarction Instrument (QLMI) or QLMI-2) [45]	27 items assessing three factors: social functioning, physical functioning and emotional functioning.
Seattle Angina Questionnaire (SAQ) [46]	Five scales to assess dimensions of coronary artery disease: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. Demonstrated to be responsive to both major changes in clinical status (i.e., improvement in angina-related problems as a result of angioplasty) and smaller changes in angina-related functional status.
Myocardial Infarction Dimensional Assessment Scale [47]	Covers seven areas of health status (physical activity, insecurity, emotional reaction, dependency, diet, concerns over medications and side effects).
Physical Activity Score [48]	Evaluates one dimension in estimating physical capacity for patients with angina pectoris

is a metric utilized in outcomes research that incorporates both longevity and QoL and provides a common scale to compare different therapies. Since many medical interventions are associated with a variety of clinical outcomes, the QALY is an invaluable common metric that affords the ability to compare very different interventions.

Health status measures can be generic, in that they are applicable to heterogeneous populations with varying diseases and comorbidities, or disease-specific (i.e.,

explicitly designed to assess the burden of SIHD, including the symptoms of angina and its associated limitations) [52–55]. One disease-specific tool for assessing angina is the Seattle angina questionnaire (SAQ) which is a 19-item self-administered questionnaire measuring five domains affected by angina: physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception. It was validated against measures such as physician diagnoses, nitroglycerin refills, and exercise duration and has

4 Blankenship et al.

subsequently been shown to be prognostic of outcome [56]. The SAQ can distinguish treatment effect from the influences of comorbid illness and is more sensitive to subtle changes in clinical condition than are generic measurement tools [46,57].

Some symptoms of active ischemic heart disease (e.g., dyspnea/shortness of breath, energy/fatigue) are not well captured in the current disease-specific scales but may be important to patients [58]. The absence of these dimensions from QoL measures may lead to underestimation of the benefits of therapies for SIHD.

Outcomes After PCI in Patients Presenting With STEMI/NSTE-ACS

Studies of outcomes after STEMI/NSTE-ACS have generally focused on adverse events such as recurrent MI, recurrent ischemia, and late revascularization rather than QoL. Since these outcomes are known to affect QoL, they are briefly summarized here.

Primary PCI for STEMI has several advantages compared with fibrinolytic therapy. In pooled analyses, primary PCI is associated with reduced mortality, stroke, intracranial hemorrhage, reinfarction, and recurrent ischemia compared with fibrinolysis [2,59–62]. Analyses examining 12 month costs in terms of cost per event-free survivor found that expenditures were lower in the PCI cohorts than in the fibrinolytic-treated patients [63–66]. For STEMI, use of stents compared with balloon angioplasty is associated with early (i.e., 6 months) improvement in QoL as manifested as reduced angina frequency, less bodily pain, and improved disease perception [67].

A routine invasive strategy in patients with NSTEMI-ACS reduces (a) the composite risk of death or non-fatal MI [6,68] (particularly in patients with ischemic ECG changes, positive biomarkers, or advanced age), (b) severe angina [6,69], and (c) rehospitalization over the ensuing 1–2 years [6], as compared with an ischemia-guided approach. Compared with a non-invasive strategy, an invasive strategy reduces (a) duration of initial hospital stay [70,71], (b) readmission rate [71–73], (c) anginal symptoms [69,71,74], and (d) the number of required anti-anginal medications [71,74]. Studies have also demonstrated greater gains in QoL with an invasive strategy leading to PCI when appropriate compared with a strategy of medical therapy in ACS patients [74–77].

QoL After PCI in Patients With SIHD

Several types of studies have been used to evaluate the effect of PCI on QoL in SIHD patients. Observational cohort studies that compare baseline to post-PCI QoL provide the lowest quality of evidence, as they are

subject to bias and placebo effect and likely exaggerate the true benefits of PCI (Table III). Observational studies that compare patients undergoing PCI to a cohort receiving medical therapy alone or coronary artery bypass graft (CABG) surgery (Table IV) provide higher quality evidence, but are still subject to bias. The highest quality evidence comes from randomized controlled studies comparing PCI to alternative treatments (Tables V and VI), although these are also subject to enrollment biases that may prevent prescription of the very patients who might benefit most, and to crossover that obscures the effects of the original treatment assignment.

Multiple studies have demonstrated that PCI improves QoL [9,10,52,54,55,58,78–86,89,93,103–110] and exercise capacity [78,79,85,86,111] compared with pre-PCI status. The magnitude of improvements in QoL correlated with improvements in outcomes following PCI [112].

Effect of PCI on QoL Compared With Medical Therapy

In studies of patients with SIHD, PCI has been more effective than medical therapy in relieving angina [8,11,87,94,97,106,113–119], reducing the use of anti-anginal drugs [117], and improving exercise capacity [8] and QoL [9,58,82,94,114] (Tables III and IV). Improved QoL with PCI compared with medical therapy (Table V) has been reported at late follow-up 5–8 years post procedure [114,118] but not at 3 years post procedure [113].

A meta-analysis of 14 randomized, controlled trials of PCI versus medical therapy in 7,818 patients enrolled from 1987–2005 showed that complete angina relief was superior with PCI (odds ratio: 1.69, 95% confidence interval: 1.24–2.30) [120] with the benefit limited to trials that enrolled patients before the year 2000. In pooled analysis of studies that enrolled patients after 2000, angina relief was similar for both therapies, which may be attributable to improved medical therapy. An alternative explanation is that the recent studies in this analysis enrolled patients with a low prevalence of significant angina at baseline. Specifically, two-thirds of patients in the Clinical Outcomes Utilizing Revascularization and Aggressive drug Evaluation trial [COURAGE] [113] had angina weekly or less frequently and 77% in the Open Artery Trial (OAT) [100] had no angina, perhaps rendering PCI—or any intervention—unlikely to improve angina symptom control. Non-randomized studies enrolling patients after 2000 with a higher prevalence of angina than COURAGE or OAT have demonstrated significantly better QoL with PCI compared with medical therapy [9,82,87,94,97,116–119].

T3
T4
T5
T6

TABLE III. Studies of Quality of Life (QoL) Post-Percutaneous Coronary Intervention (PCI) versus Pre-PCI in PCI Cohort Studies

Author date	Study design	N (PCI patient)	QoL Tool(s)	Angina-Free (Pre-PCI/Post/PCI)	Summary of Status Post-PCI (compared with Pre-PCI)
PCI Cohort in Single Cohort Studies (PCI only)					
Bliley, 1993 [78]	Prospective cohort of PCI patients	40	Ferrans and Powers Quality of Life Index Cardiac Version	10% pre/72% post, $P < 0.0002$ at 6 weeks	Significant improvement in all domains of QoL at 6 weeks
McKenna, 1994 [79]	Prospective cohort of PCI patients	209	General Health Questionnaire	Angina improved in 72% of patients at 1 month	QoL improved at 2 and 11 months
Permanyer-Miralda, 1999 [80]	Prospective cohort of PCI patients	106	Nottingham Health Profile (NHP), DASI	0% pre/70% post at 3 years	NHP and DASI both statistically significantly improved at 1 month and 3 years ($P < 0.01$)
Seto, 2000 [81,82]	Prospective cohort of PCI patients	1445	SF-36, SAQ	nr	QoL improved in 58–75% of patients for different domains at 6 months
Spertus, 2004 [82]	Prospective cohort of PCI patients	1020	SAQ	nr	85% had “clinically significant improvement” at 1 year
Lowe, 2004 [83]	Prospective cohort of PCI patients “not appropriate for PCI”	21	SAQ	nr	No significant improvement in any domain at 1 year
Wong, 2007 [84]	Prospective cohort of Chinese PCI patients	78	SF-36, SAQ	nr	Statistically significant improvements in 6 of 8 SF36 and 5 of 5 SAQ domains at 1 and 3 months
Grantham, 2010 [85]	Prospective cohort of PCI patients with chronic total occlusion	125	SAQ	nr	“significant improvement” in QoL at 1 month
Melberg, 2010 [86]	Prospective cohort of PCI patients	609	SF-36	nr	“Significant improvement” in nearly all domains at 6 months
De Quadros, 2011 [87]	Prospective cohort of PCI patients	110	SAQ	5% pre/68% post ($P < 0.001$) at 1 year	“Significant clinical improvement” in >70% of patients in 4 out of 5 SAQ domains at 6 and 12 months
PCI Cohort in Multi-Cohort Studies					
Brorsson, 2001 [43]	Prospective cohorts of PCI and CABG patients	349	SWED-QUAL	3% pre/51% post ($P < 0.05$) at 4 years	Statistically significant improvements in all 5 domains of SWED-QUAL at 6, 21, and 48 months
Borkon, 2002 [88]	Prospective cohorts of PCI and CABG patients	252	SAQ	nr	All domains of SAQ improved at 6 and 12 months
Kattainen, 2005 [89]	Prospective cohorts of PCI and CABG patients	183	15D	nr	QoL significantly improved versus baseline at 6 and 12 months.
Loponen, 2009 [90]	Prospective cohorts of PCI and CABG patients	229	15D	2% pre/58% post at 3 years	QoL better at 6 months but not at 3 years; angina better at 6 months and 3 years
Van Dornburg, 2010, ARTS II [91]	Prospective cohorts of PCI and CABG patients	585	SF-36	7% pre/90% post at 3 years	Significant improvement in all 8 domains of SF-36 at 6 months and 3 years
Brooks, 2010 BARI-2D [92]	Prospective cohort of PCI patients and CABG patients	796	DASI, Rand scales	17% pre/60% post	Data not available for PCI group alone

ARTS, Arterial Revascularization Therapies Study; BARI-2D, Bypass Angioplasty Revascularization Investigation—2 Diabetes; CABG, coronary artery bypass graft surgery; DASI, Duke Activity Status Index; Nr, Not reported; PCI, Percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire; SF-36, Short Form 36; SWED-QUAL, Swedish Quality of Life Survey.

6 Blankenship et al.

TABLE IV. Studies of Quality of Life (QoL) Post-Percutaneous Coronary Intervention (PCI) versus Pre-PCI in PCI Arm of Randomized Studies

Author, date, trial name	Study design	N	QoL tool(s)	Angina-free (Pre-PCI/Post/PCI)	Summary of status post-PCI (compared with pre-PCI)
Pocock, 2000, RITA-2 [58]	Randomized to PCI versus medical therapy	504	SF-36	nr	33% rated health at 1 year as "much better"; QoL better at 3 and 12 months
Strauss 1995, ACME [8]	Single vessel coronary disease randomized to PCI versus medical therapy	105	McMaster Health Index Questionnaire	23% pre/73% post at 6 months	Angina and QoL better at 6 months
Folland, 1997, ACME [93]	Two vessel coronary disease randomized to PCI versus medical therapy	51	McMaster Health Index Questionnaire	20% pre/53% post at 6 months	Angina and QoL better at 6 months
Pitt, 1999, AVERT [10]	Randomized to PCI versus atorvastatin	177	SF-36	Angina improved in 54% at 18 months	QoL improved at 6 and 18 months
Favarato, 2007, MASS II [94]	Randomized to PCI versus medical therapy	180	SF-36	nr	QoL improved at 6 and 12 months
Weintraub, 2008, COURAGE [9] [95]	Randomized to PCI versus medical therapy	1149	RAND-36 SAQ	21% pre/59% post at 3 years	QoL score improved approx 50% at 6, 12, 24, and 36 months
Wahrborg, 1999, CABRI [96]	Multi-vessel coronary disease randomized to PCI versus CABG versus medical therapy	74	Nottingham Health Profile (NHP)	nr	All 8 NHP domains improved at 1 year ($P < 0.01$)
Zhang, 2003, SoS Trial [97]	Multivessel coronary disease randomized to PCI or CABG	488	SAQ	nr	QoL improved at 6 months and 1 year ($P < 0.01$)
Thiele, 2009 [98]	Isolated proximal left anterior descending disease randomized to PCI or CABG	65	SF 36, McNew	nr	All 8 SF-36 and all 4 McNew domains improved at 1 year, all $P < 0.01$
Cohen, 2011, SYNTAX [99]	Multi-vessel or left main coronary disease randomized to PCI or CABG	903	SF-36, SAQ	22% pre/72% post at 12 months	QoL score improved significantly from approx 45 at baseline to approx 75 at 6 and 12 months

ACME, angioplasty compared with medical therapy; AVERT, atorvastatin versus revascularization treatment; CABG, coronary artery bypass graft surgery; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; CABRI, coronary angioplasty versus bypass revascularization investigation; MASS II, medicine, angioplasty, or surgery study; NHP, Nottingham health profile; NR, not reported; PCI, percutaneous coronary intervention.

The misperception that PCI improves QoL only minimally may be fueled by a misunderstanding of the COURAGE [113] and Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) [92] treatment strategies. Since these studies compared medical therapy with revascularization as initial treatment strategies, crossover from medical therapy to revascularization therapy for relief of unacceptable symptoms was frequent (33% of patients in COURAGE and 42% of patients in BARI-2D). Because higher than anticipated crossover rates in clinical trials reduces the ability to detect differences in the treatment groups this may have obscured long-term differences in symptoms between the initial treatment assignment to PCI or medical therapy [92,113].

The writing group could find only two studies failing to show a benefit of PCI on QoL. Patients randomized to PCI versus exercise training reported similar improvements in angina [105]. In patients deemed unsuitable for any revascularization, salvage PCI did not improve QoL but slightly improved angina status compared with baseline [83].

Effect of PCI on QoL Compared With CABG

Many studies have compared PCI with CABG for angina control and QoL improvement (Table VI). Both procedures improve angina and QoL compared with baseline [88,91,94,96,97,99,121,122]. QoL is better after PCI than after CABG in the first months after the

TABLE V. Studies of Quality of Life (QoL) After Percutaneous Coronary Intervention (PCI) Compared With Medical Therapy

Author, date, trial name	Study design	N, (PCI/medical therapy)	QoL tool(s)	Angina-free (post-PCI/post medical therapy (MT))	Summary of status post-PCI (compared with Post MT)
Pitt, 1999, AVERT [10]	Randomized to PCI versus atorvastatin	177/164	SF36	nr	QoL similar at 6 and 18 months for PCI and MT. Both groups improved from baseline
Pocock, 2000, RITA-2 [77]	Randomized to PCI versus MT	504 /514	SF-36	65% PCI/ 47% MT (<i>P</i> < 0.05) at 1 year	QoL better than MT for PCI at 3 months and 1 year but not at 3 years.
Strauss, 1995, ACME [8]	Randomized to PCI versus MT for 1-vessel disease	105 /107	McMaster Health Index Questionnaire	nr	QoL scores better in PCI than in MT at 6-month
Folland, 1997, ACME [93]	Randomized to PCI versus MT for 2-vessel disease [93]	51 /50	McMaster Health Index Questionnaire	53% PCI/36% MT (<i>P</i> = 0.09) at 6 months	QoL similar for PCI and MT at 6 months.
Favarato, 2007, MASS II [94]	Randomized to PCI versus MT	180 /187	SF-36	nr	QoL better for PCI than MT at 12 months
Weintraub, 2008; Zhang, 2011, COURAGE [9] [95]	Randomized to PCI versus MT	1149 /1138	RAND-36 SAQ	53% PCI versus 42% MT (<i>P</i> <0.001) at 3 months	Both groups improved from baseline. QoL better for PCI than MT at 3 and 6 months but similar at 12 months
Mark, 2009, OAT [100]	Post MI occluded infarct vessel randomized to PCI versus MT	1082 /1084	DASI SF-36	93% PCI / 88% MT (<i>P</i> = 0.03) at 24 months	QoL better with PCI at 6 months but not at 12 or 24 months by DASI; no difference by SF-36 at 6, 12, or 24 months

ACME, angioplasty compared with medical therapy; AVERT, atorvastatin versus revascularization treatment; BMS, bare metal stents; CABG, coronary artery bypass graft surgery; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; DASI, duke activity status Index; DES, drug eluting stents; MASS, medicine, angioplasty, or surgery study; MI, myocardial infarction; nr, not reported; NHP, Nottingham health profile; PCI, percutaneous coronary intervention; OAT, occluded artery trial; PTCA, percutaneous transluminal coronary angioplasty; QoL, quality of life; RITA, randomized intervention treatment of Angina; SAQ, Seattle angina questionnaire; SF, short form. TIME, trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary artery disease.

procedure [88,90,99,109,123–126]. Return to work occurs earlier with PCI-treated patients compared with CABG, but at 3–5 months the rate is similar [40,124,127].

Fewer patients reported angina at 1 year follow-up with CABG compared with PCI in a collaborative analysis of data from 6,528 patients enrolled in 10 randomized trials of CABG versus PCI (14% versus 26%, *P* < 0.001) [128]. A systematic review of 23 randomized studies of CABG versus PCI reported that angina relief at 1, 3, and 5 years was better for CABG than PCI [129]; at 5 years the incidence of freedom from angina was 84% for CABG and 79% for PCI (*P* < 0.001). Most but not all observational studies document better angina relief and QoL with CABG at 6 months to 4 years of follow-up when compared with PCI [52,90,117,126,130].

Drug eluting stents (DES) compared with historic CABG controls were associated with better QoL at 1

year and similar QoL at 3 year follow-up [91]. The SYNERgy Between PCI with TAXus and Cardiac Surgery (SYNTAX) trial demonstrated a small but significant reduction in angina frequency with CABG compared with DES at 6 and 12 months in patients who had frequent (i.e., daily or weekly) angina at baseline, but not in those with less frequent symptoms [99].

With long-term follow-up (e.g., >5 years), differences in angina-free status between PCI and CABG tend to decrease due to return of angina in CABG patients and cross-over to CABG in patients initially treated with PCI [102,131]. Findings during long-term follow-up stem, in part, from the fact that stent failure tends to occur over months, while vein graft attrition and related symptoms onset over years.

In patients with left main or single vessel proximal left anterior descending artery disease, PCI (compared with CABG) produced similar QoL at 6–12 months [98,132–134] but more frequent angina at 5 years [11].

8 Blankenship et al.

TABLE VI. Selected Studies of Quality of Life (QoL) After Percutaneous Coronary Intervention (PCI) Compared With Coronary Artery Bypass Surgery (CABG)

Author, date, trial name	Study design	N (PCI/CABG)	QoL tool(s)	Angina-free (post-CABG/Post PCI)	Summary of status post-PCI (compared with Post-CABG)
Brorsson 2001, Sweden [52]	Cohort with chronic stable angina and 1- or 2-vessel disease	252/349	SWED-QUAL	57% CABG/51% post PCI at 4 years	QoL better with CABG at 6 months but similar at 4 years on all scales.
Brorsson, 2002, Sweden [101]	Cohort with chronic stable angina	256/757	SWED-QUAL		QoL better with CABG at 6 and 21 months ($P < 0.05$) in 4 of 5 domains
Pocock, 1996, RITA [55]	Randomized to PCI versus CABG	510/501	NHP	78% CABG/ 69% PCI ($P = 0.007$) at 2 years	QoL borderline significantly better for CABG than PCI at 6 months and 2 years
Wahrborg, 1999, CABRI [96]	Multivessel CAD randomized to PCI or CABG or medical therapy	74/80	NHP	nr	QoL similar for PCI and CABG at 1 year
Borkon, 2002 [88]	Cohort undergoing PCI or CABG	252 /223	SAQ	nr	Angina frequency and QoL better for CABG than PCI at 6 and 12 months
Zhang, 2003, SoS Trial [97]	Multivessel CAD randomized to PCI versus CABG	488 /500	SAQ	nr	Angina frequency and QoL better with CABG at 6- and 12-months.
Favarato, 2007, MASS II [94]	Multi-vessel coronary disease randomized to PCI or CABG or medical therapy	180/175	SF-36	nr	QoL for CABG better than PCI at 1 year. QOL for CABG and PCI better than with medical therapy at 1 year
Hlatky, 2004, BARI [102]	Multi-vessel coronary disease randomized to PCI versus CABG versus medical therapy	465/ 469	DASI and Rand Mental Health Inventory 5 Scale	nr	QoL better for CABG than PCI through 3 years but similar from 3–10 years
Thiele, 2009 [98]	Isolated proximal left anterior descending disease randomized to PCI versus CABG	65/65	SF 36, McNew	CABG 74% /PCI 81% ($P = 0.05$) at 12 months	QOL similar for PCI and CABG
Van Dornburg, 2010, ARTS II [91]	DES cohort (compared with historical controls randomized to BMS versus CABG)	583 = (DES) 483 = (BMS) 492 = (CABG)	SF-36	CABG 87.0%/ PCI with DES 90.0% / 80% PCI with BMS at 12 months	QoL better after DES than CABG up to 1 year and similar at 3 years
Cohen, 2011, SYNTAX [99]	Multi-vessel or left main coronary disease randomized to PCI versus CABG [99]	903 /897	SF-36 SAQ	Similar at 1 and 6 months; CABG 76% versus PCI 72%, $P = 0.05$ at 1 year	QoL better for PCI at 1 month and worse for PCI at 12 months compared with CABG

ACME, angioplasty compared with medical therapy; ARTS, arterial revascularization therapies study; BARI, bypass angioplasty revascularization investigation; BMS, bare metal stents; CABG, coronary artery bypass graft surgery; CABRI, Coronary Angioplasty versus Bypass Revascularization Investigation; CAD, coronary artery disease; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; DASI, duke activity status index; DES, drug eluting stents; NHP, Nottingham health profile; NS, not significant; OAT, occluded artery trial; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; QoL, quality of life; RITA, randomized interventions treatment of angina; SAQ, Seattle angina questionnaire; SF, short form, SoS, stent or surgery; SYNTAX, SYnergy between PCI with TAXUS and CABG.

QoL After PCI in Specific Patient Subsets

Gender. QoL is better in men who undergo revascularization for CAD as compared with similarly treated women [87,92,94,117,135,136]. This finding is due in part to the facts that men report better QoL at baseline compared with women, and baseline QoL is a strong predictor of post-revascularization QoL. Another con-

tributing factor is that women have more recurrent angina after PCI than men [137,138].

Elderly. Elderly patients with symptomatic CAD have improved QoL with PCI and derive a similar or greater improvement than younger patients, despite having a higher risk profile at presentation [81,82,85,104,108 139–141]. Neither of the age-specific

subgroups in the SYNTAX trial (<75-year old versus >75-year old) had differences between PCI and CABG in the SAQ angina frequency subscale at 6 or 12 months; there was no interaction between age and angina status. [99].

Diabetes. The BARI 2D trial showed improvement in angina with PCI compared with medical therapy, but otherwise similar QoL measurements [92,115]. The SYNTAX trial did not demonstrate significant differences in QoL scores for CABG versus PCI-treated diabetic patients [99].

Prior CABG. In a retrospective study of patients with recurrent ischemia following CABG, PCI of the native vessel or bypass graft significantly improved angina compared with baseline [142].

Other Subgroups. Data regarding QoL after PCI in patients with chronic kidney disease or congestive heart failure is lacking.

Factors Affecting QoL After PCI

Not all patients who undergo PCI experience improved QoL [8,55,107,143]. Post-PCI QoL is affected by several factors (Table VII).

Increased frequency of angina and greater extent of myocardial ischemia at baseline correlate with greater improvements in QoL after PCI [9,82,85,96,99,145,15], as do post-PCI freedom from angina [55,80,89,152,158,159] and freedom from repeat revascularization post-PCI [153]. However, patients attach limited importance to repeat PCI for restenosis [160]. A time trade-off study demonstrated that patients would be willing to sacrifice less than a week of life out of an expected 10-year life span to avoid an episode of restenosis [161].

In randomized trials, cardiac rehabilitation reduces hospital readmission and clinical event rates and improves QoL after PCI [146,147]. Non-smoking status after PCI correlated with better QoL compared with smoking [92,144,146] and patients that quit have better health status outcomes than those that continue smoking [144,150]. Co-morbidities (e.g., depression, congestive heart failure, increasing body mass index and neuropathy) [54,80,92,162], lower socioeconomic status [153], and unemployed status [55,154] after PCI correlate with lower QoL.

Sexual activity is a component of QoL [155]. Sexual dysfunction is more prevalent in patients with SIHD [163], but it is unclear whether it is improved by PCI [164]. Patients with erectile dysfunction may be unable to take phosphodiesterase inhibitors (e.g., sildenafil) because they have angina treated with long-acting nitrates or sub-lingual nitroglycerine. PCI that removes the need for nitrates and allows use of phosphodiester-

ase inhibitors to treat erectile dysfunction might improve sexual functioning and QoL in selected patients [165].

Ethical Principles in Decisions Regarding Therapy and QoL

The fundamental principles of medical ethics are beneficence (“do good, avoid harm”), autonomy, and distributive justice [166]. The first two are most relevant to PCI and QoL. Beneficence represents the duty of the physician to provide care that produces the greatest benefit to the patient. Autonomy describes the physician’s responsibility to help the patient make informed decisions. These principles should influence how physicians conduct informed consent discussions and advise patients about preferred therapies [167].

Informed Consent. The physician has the responsibility for presenting treatment options and the pros and cons of each alternative [167]. This may require inquiry into the patient’s values to identify important preferences. The physician should discuss the likelihood of survival, MI, stroke, repeat revascularization procedures, and QoL associated with the treatment options. This discussion should be personalized for each patient to include anticipated risks and benefits. For many patients, the treatment options carry similar risks of death and MI and therefore QoL assumes relatively greater importance. In these cases, physicians should explain that for some but not all patients QoL is most improved by PCI or CABG in the most symptomatic patients, and least improved with revascularization in patients who are asymptomatic or only mildly symptomatic.

Advising Patients on Choice of Strategy. For most patients, survival dictates the choice of treatment strategy. When survival is similar among various strategies, patients usually base decisions on their perceptions of how each strategy affects QoL.

Given a choice, most patients prefer a strategy that is easier in the short-term (e.g., PCI) over a strategy that is more complicated in the short-term (e.g., CABG), even when the more complicated strategy produces better long-term results (e.g., less angina or better QoL). Since most patients make these value judgments—so called temporal discounting—without this understanding [168], the physician should make patients aware of the trade-offs they are considering.

Cardiologists face several challenges to their objectivity when making treatment recommendations. First, patients and physicians frequently over-estimate the benefit of revascularization procedures compared with noninvasive medical therapies [12,13–15,169]. Second, physicians express more regret about adverse

TABLE VII. Studies Identifying Predictors of Post-Percutaneous Coronary Intervention (PCI) Quality of Life (QoL)

Author, date, reference	Population	N	Factors Correlating with Poor Post-PCI Quality of Life		Improvement in QoL correlates with severity of baseline angina
			Baseline poor health status	Other factors	
McKenna, 1994 [79]	Post-PCI	209	nr	Restenosis/ revascularization	nr
Nash, 1999 [54]	Post-PCI	1182	+	Prior CABG, elderly	nr
Permanyer-Miralda, 1999 [80]	Post-PCI	106	+	Post-PCI angina, dyspnea, restenosis/ revascularization	nr
Taira, 2000 [145]	Post-PCI	1432	nr	Continued smoking post-PCI	nr
Bourassa, 2000 [146]	Post PCI or CABG in BARI Trial	1095	nr	nr	+
Belardinelli, 2001 [147]	Post-PCI	118	nr	Randomization to no exercise training	nr
Rumsfeld, 2001 [127]	Post-PCI or CABG	389	+	COPD, CKD, diabetes, current smoker	nr
Higgins, 2001 [148]	Post-PCI	99	nr	Randomization to no cardiac rehab	nr
Brorsson, 2001 [149]	Post-PCI or CABG	601	nr	Female, heart failure	nr
Jamieson, 2002 [150]	Post-PCI or CABG	301	+	Female elderly	nr
Borkon, 2002 [88]	Post-PCI	252	nr	Restenosis/ revascularization	nr
Haddock, 2003 [151]	Post-PCI	271	nr	Current smoker	nr
Zhang, 2003 [97]	Post-PCI	488	nr	Restenosis/ revascularization	nr
Zhang, 2004 [136]	Post-PCI in SOS Trial	388	nr	Female	nr
Hlatky, 2004 [152]	Post-PCI or CABG in BARI Trial	934	nr	nr	+
Spertus, 2004 [82]	Post-PCI	1518	+	Age	+
Spertus, 2005 [153]	Post-PCI	1027	nr	High risk for restenosis	nr
Denvir, 2006; Leslie, 2007 [154,155]	Post-PCI	1346	nr	Low socioeconomic status, unemployment	nr
Hofer, 2006 [124]	Post-PCI	432	nr	Depression, anxiety	nr
Favarato, 2007 [94]	Post-PCI	180	nr	Female	nr
Weintraub, 2008 [9]	Post-PCI in COURAGE	1149	nr	nr	+
Kriston, 2010 [156]	Post-PCI or CABG	493	nr	Sexual dysfunction, depression	nr
Grantham, 2010 [85]	Post-PCI	125	nr	nr	+
Brooks, 2010 [92]	Post-PCI or CABG in BARI-2D Trial	2368	nr	Female, elderly, angina, smoking, heart failure	nr
Rittger, 2011 [157]	Post-PCI	95	nr	Elderly	nr
De Quadros, 2011 [87]	Post-PCI	110	+	nr	+

BARI, bypass angioplasty revascularization investigation; BARI-2D, bypass angioplasty revascularization investigation—2 diabetes Trial; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COURAGE, Clinical outcomes utilizing revascularization and aggressive drug evaluation trial; nr, not reported; PCI, percutaneous coronary intervention; QoL, quality of life; SoS, stent or surgery trial.

outcomes associated with inaction (not performing PCI) than complications associated with performing PCI (the “chagrin factor”) [170] even though the outcome may be the same (i.e., death of the patient). Third, the reimbursement model for United States health care incentivizes performance of procedures. Therefore, the physician must accurately advise the patient about the pros and cons of each treatment alternative and help the patient arrive at the treatment decision most consistent with the patient’s values and preferences [128].

CONCLUSIONS AND RECOMMENDATIONS

1. While the overriding goal in performing PCI in patients with STEMI and NSTEMI-ACS is to reduce morbidity and mortality, appropriate early cardiac catheterization and PCI is associated with improved QoL in patients without serious comorbidities.
2. PCI for treatment of SIHD improves QoL and angina, compared with baseline, and compared with medical therapy, with the following limitations:

- a. QoL improvement after PCI is proportional to the severity of angina before PCI and adequacy of revascularization.
 - b. Some co-morbidities limit QoL before and after PCI and may minimize any improvement in QoL resulting from PCI.
 - c. QoL benefits of PCI over medical therapy decrease over time due to cross-over from medical therapy to PCI, the efficacy of optimal medical therapy, and restenosis or progression of atherosclerosis.
3. QoL after PCI compared with CABG is better in the short-term (months), worse in the intermediate term (1–5 years), and probably similar in the long-term (>5 years) due to bypass graft failure, progression of atherosclerosis in native vessels, and cross-over from PCI to CABG.
 4. Many SIHD patients and physicians tend to overestimate the benefits of revascularization procedures and underestimate the safety and effectiveness of medical therapy.
 5. When there is equipoise in the risks/benefits of medical therapy compared with PCI, the preferences of the fully informed patient should play a major role in treatment decisions.
 6. Policymakers should consider QoL issues and allow for patient preferences when developing clinical trials, appropriate use criteria, practice guidelines, and reimbursement policies for PCI.
 7. The importance of QoL issues should be considered in all aspects of PCI care from the physician's initial assessment of potential benefit through the public reporting of results.
 8. Additional research is needed to accomplish the following:
 - a. Prospectively document the baseline and follow-up QoL in SIHD patients treated with medical therapy alone versus medical therapy with PCI versus medical therapy with CABG, including specific subgroups such as women, diabetics, the elderly, and those with chronic kidney disease, heart failure, or prior CABG.
 - b. Identify subgroups of SIHD patients for whom PCI is particularly effective in improving QoL (e.g., patients with QoL limited only by severe angina) and for whom PCI is relatively *ineffective* in improving QoL (e.g., patients with minimal angina or with baseline poor QoL due to multiple intractable co-morbidities). Build prediction models of health status outcomes that could better inform patients and physicians of likely outcomes of medical therapy, PCI, and CABG.
 - c. Identify optimal methods of educating patients and physicians about expected outcomes of different treatment options and integrate optimal

education methods into routine informed consent processes.

New innovations in revascularization and medical therapy will require ongoing reassessment of QoL after PCI. For example, most of the studies cited here did not use DES; reductions in restenosis due to DES may further improve QoL post-PCI. Additional insights into post-PCI QoL are expected from the proposed International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial randomizing 8,000 patients with moderate ischemia on stress testing to catheterization and revascularization versus optimal medical therapy.

In summary, PCI decreases mortality and ischemic events and improves QoL in patients with STEMI and NSTEMI-ACS. In SIHD patients, PCI may improve symptoms and QoL, with the greatest benefits in patients with few co-morbidities, severe angina, and potential for complete revascularization. SIHD patients with severe co-morbidities or minimal ischemic symptoms benefit minimally from PCI. For many SIHD patients, an initial treatment strategy of PCI is superior to medical therapy in improving QoL in the short-term. QoL differences between PCI versus CABG vary as time elapses after the procedure. QoL differences among these treatment strategies are small enough and individual patients' responses to treatment are variable enough that patient preferences must be considered in choosing treatment strategies for SIHD.

ACKNOWLEDGEMENTS

The authors acknowledge critical review and helpful comments from Drs William E. Boden, David J. Cohen, Spencer B. King III, Glenn N. Levine, John A. Spertus, Peter H. Stone, and the official reviewer for the Society for Cardiovascular Angiography and Interventions.

REFERENCES

1. Blankenship JC, Scott TD, Skelding KA, Haldis TA, Tompkins-Weber K, Sledgen MY, Donegan MA, Buckley JW, Sartorius JA, Hodgson JM, Berger PB. Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. *J Am Coll Cardiol* 2011;57:272–279.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. *Lancet* 2003;361:13–20.
3. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, Lips DL, Madison JD, Menssen KM, Mooney MR, Newell MC, Pedersen WR, Poulouse AK, Traverse JH, Unger BT, Wang YL, Larson DM. A regional system to provide timely access to percutaneous coronary intervention

Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.

Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

12 Blankenship et al.

- for ST-elevation myocardial infarction. *Circulation* 2007; 116:721–728.
4. Ting HH, Rihal CS, Gersh BJ, Haro LH, Bjerke CM, Lennon RJ, Lim CC, Bresnahan JF, Jaffe AS, Holmes DR, Bell MR. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: The Mayo Clinic STEMI Protocol. *Circulation* 2007;116:729–736.
 5. Zhang S, Ge J, Yao K, Qian J. Meta-analysis of early versus deferred revascularization for non-ST-segment elevation acute coronary syndrome. *Am J Cardiol* 2011;108:1207–1213.
 6. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials. *JAMA* 2005;293:2908–2917.
 7. Chan PS, Patel MR, Klein LW, Krone RJ, Dehmer GJ, Kennedy K, Nallamothu BK, Weaver WD, Masoudi FA, Rumsfeld JS, Brindis RG, Spertus JA. Appropriateness of percutaneous coronary intervention. *JAMA* 2011;306:53–61.
 8. Strauss WE, Fortin T, Hartigan P, Folland ED, Parisi AF. A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. *Circulation* 1995;92:1710–1719.
 9. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkowitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. *N Engl J Med* 2008;359:677–687.
 10. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* 1999;341:70–76.
 11. Hueb WA, Soares PR, Almeida De Oliveira S, Arie S, Cardoso RH, Wajsbrot DB, Cesar LA, Jatene AD, Ramires JA. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. *Circulation* 1999;100:107–113.
 12. Poses RM, Krueger JI, Sloman S, Elstein AS. Physicians' judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease. *Chest* 2002;122:122–133.
 13. Kee F, McDonald P, Gaffney B. Risks and benefits of coronary angioplasty: The patients perspective: A preliminary study. *Qual Health Care* 1997;6:131–139.
 14. Whittle J, Conigliaro J, Good CB, Kelley ME, Skanderson M. Understanding of the benefits of coronary revascularization procedures among patients who are offered such procedures. *Am Heart J* 2007;154:662–668.
 15. Rothberg MB, Sivalingam SK, Ashraf J, Visintainer P, Joelson J, Kleppel R, Vallurupalli N, Schweiger MJ. Patients' and cardiologists' perceptions of the benefits of percutaneous coronary intervention for stable coronary disease. *Ann Intern Med* 2010;153:307–313.
 16. Holmboe ES, Fiellin DA, Cusanelli E, Remetz M, Krumholz HM. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. *J Gen Int Med* 2000;15:632–637.
 17. Brindis R, Goldberg SD, Turco MA, Dean LS. President's page: Quality and appropriateness of care: The response to allegations and actions needed by the cardiovascular professional. *J Am Coll Cardiol* 2011;57:111–113.
 18. Gardner AW, Montgomery PS, Ritti-Dias RM, Thadani U. Exercise performance, physical activity, and health-related quality of life in participants with stable angina. *Angiology* 2011;62:461–466.
 19. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;58:e44–122.
 20. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. *Eur Heart J* 2010;31:2501–2555.
 21. Campeau L. Letter: Grading of angina pectoris. *Circulation* 1976;54:522–523.
 22. Hlatky MA. Patient preferences and clinical guidelines. *JAMA* 1995;273:1219–1220.
 23. Bliven BD, Green CP, Spertus JA. Review of available instruments and methods for assessing quality of life in anti-anginal trials. *Drugs Aging* 1998;13:311–320.
 24. Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F. Changes in quality of life after renal transplantation. *Am J Kid Dis* 1998;32:93–100.
 25. Franke GH, Reimer J, Philipp T, Heemann U. Aspects of quality of life through end-stage renal disease. *Qual Life Res* 2003;12:103–115.
 26. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. *Chest* 1994;106:324S–328S.
 27. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. *Lung Cancer* 1995;12:45–58.
 28. Ethgen O, Bruyere O, Richey F, Dardennes C, Reginster JY. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. *J Bone Joint Surg Am* 2004;86A:963–974.
 29. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. *Health Qual Life Outcomes* 2004;2:2.
 30. Nilsson AK, Petersson IF, Roos EM, Lohmander LS. Predictors of patient relevant outcome after total hip replacement for osteoarthritis: A prospective study. *Ann Rheum Dis* 2003; 62:923–930.
 31. Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blanche G, Sato R, Stoeckl M, Revicki DA. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. *Transplant Int* 2007;20:875–883.
 32. Pedersen SS, Versteeg H, Denollet J, Cheng JM, Serruys PW, van Domburg RT. Patient-rated health status predicts prognosis following percutaneous coronary intervention with drug-eluting stenting. *Qual Life Res* 2011;20:559–567.

Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.

Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

33. Schenkeveld L, Pedersen SS, van Nierop JW, Lenzen MJ, de Jaegere PP, Serruys PW, van Domburg RT. Health-related quality of life and long-term mortality in patients treated with percutaneous coronary intervention. *Am Heart J* 2010; 159:471–476.
34. Ferrans CE, Powers MJ. Quality of life index: Development and psychometric properties. *Adv Nurs Sci* 1985;8:15–24.
35. Chambers LW, Sackett DL, Goldsmith CH, Macpherson AS, McAuley RG. 1993. The McMaster Health Index Questionnaire: An update. New York: Springer.
36. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care* 1994;32:40–66.
37. Muller-Nordhorn J, Roll S, Willich SN. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease. *Heart* 2004;90:523–527.
38. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220–233.
39. Hunt SM, McEwen J, McKenna SP. Measuring health status: A new tool for clinicians and epidemiologists. *J R Coll Gen Pract* 1985;35:185–188.
40. Dupuy H. The Psychological General Well-being (PGWB) Index. Connecticut: Le Jacq; 1984.
41. Kaplan RM, Bush JW, Berry CC. Health status: Types of validity and the index of well-160.
42. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: Validation of a health status measure. *Med Care* 1976;14:57–67.
43. Brorsson B, Ifver J, Hays RD. The Swedish health-related quality of life survey (SWED-QUAL). *Qual Life Res* 1993;2:33–45.
44. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). *Am J Cardiol* 1989;64:651–654.
45. Valenti L, Lim L, Heller RF, Knapp J. An improved questionnaire for assessing quality of life after acute myocardial infarction. *Qual Life Res* 1996;5:151–161.
46. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. *J Am Coll Cardiol* 1995;25:333–341.
47. Thompson DR, Jenkinson C, Roebuck A, Lewin RJ, Boyle RM, Chandola T. Development and validation of a short measure of health status for individuals with acute myocardial infarction: The myocardial infarction dimensional assessment scale (MIDAS). *Qual Life Res* 2002;11:535–543.
48. Wilson A, Wiklund I, Lahti T, Wahl M. A summary index for the assessment of quality of life in angina pectoris. *J Clin Epidemiol* 1991;44:981–988.
49. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. *Circulation* 2002;106:516–520.
50. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997;35:1095–1108.
51. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. *Med Care* 2005;43:203–220.
52. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of chronic stable angina patients 4 years after coronary angioplasty or coronary artery bypass surgery. *J Intern Med* 2001;249:47–57.
53. Brown N, Melville M, Gray D, Young T, Munro J, Skene AM, Hampton JR. Quality of life four years after acute myocardial infarction: Short form 36 scores compared with a normal population. *Heart* 1999;81:352–358.
54. Nash IS, Curtis LH, Rubin H. Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization. *Am Heart J* 1999;138:422–429.
55. Pocock SJ, Henderson RA, Seed P, Treasure T, Hampton JR. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. *Circulation* 1996;94:135–142.
56. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. *Am J Cardiol* 1994;74:1240–1244.
57. Chen AY, Daley J, Thibault GE. Angina patients' ratings of current health and health without angina: Associations with severity of angina and comorbidity. *Med Decis Making* 1996;16:169–177.
58. Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: Three-year follow-up in the RITA-2 trial. *Randomized Intervention Treatment of Angina. J Am Coll Cardiol* 2000;35:907–914.
59. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1993;328: 673–679.
60. Grines CL, Westerhausen DR, Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M, Weaver WD, Graham M, Boura J, O'Neill WW, Balestrini C, Air PAMI Study G. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: The Air Primary Angioplasty in Myocardial Infarction study. *J Am Coll Cardiol* 2002;39:1713–1719.
61. Widimsky P, Bilkova D, Penicka M, Novak M, Lanikova M, Porizka V, Groch L, Zelizko M, Budesinsky T, Aschermann M, PRAGUE Study Group I. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. *Eur Heart J* 2007;28:679–684.
62. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van't Hof AW, Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999;341:1413–1419.
63. Stone GW, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie PA, Donohue BC, Chelliah N, Vlietstra R, Catlin T, O'Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: The Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. *J Am Coll Cardiol* 1997;29:901–907.
64. Morgan KP, Leahy M, Sheehy C, Eardley P, Shotton C, Beatt KJ. UK Primary Angioplasty Cost Effectiveness Study (UK-PACES) 30 Day Outcome Data. *Heart* 2005;91:A27.
65. Stone GW, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie PA, Donohue BC, Chelliah N, Vlietstra R, Catlin T, O'Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: The Primary Angioplasty in Myocardial Infarction (PAMI)

Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.

Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

14 Blankenship et al.

- trial. The PAMI Trial Investigators. *J Am Coll Cardiol* 1997;29:901–907.
66. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. *Am J Cardiol* 1995;76:830–833.
 67. Rinfret S, Grines CL, Cosgrove RS, Ho KK, Cox DA, Brodie BR, Morice MC, Stone GW, Cohen DJ, Stent-PAMI I. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. *J Am Coll Cardiol* 2001;38:1614–1621.
 68. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. *Ann Intern Med* 2004;141:186–195.
 69. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable Angina. *Lancet* 2002;360:743–751.
 70. Thrombolysis in Myocardial Ischemia Study Group. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in myocardial ischemia. *Circulation* 1994;89:1545–1556.
 71. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol* 1995; 26:1643–1650.
 72. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast revascularisation during instability in coronary artery disease. *Lancet* 2000;356:9–16.
 73. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CM. Elevations in troponin T and I are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 sub-study. *Circulation* 2002;106:202–207.
 74. Mortensen OS, Madsen JK, Haghfelt T, Grande P, Saunamaki K, Haunso S, Hjelms E, Arendrup H. Health related quality of life after conservative or invasive treatment of inducible post-infarction ischaemia. *Heart* 2000;84:535–540.
 75. Souza EN, Quadros AS, Maestri R, Albarrán C, Sarmiento-Leite R. Preditores de mudança na qualidade de vida após um evento coronariano agudo (Predictors of quality of life change after an acute coronary event.). *Arq Bras Cardiol* 2008; 91:252–259.
 76. Kim J, Henderson RA, Pocock SJ, Clayton T, Sculpher MJ, Fox KA, RITA-3 Trial I. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). *J Am Coll Cardiol* 2005;45:221–228.
 77. Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: Three-year follow-up in the RITA-2 trial. *J Am Coll Cardiol* 2000;35:907–914.
 78. Bliley AV, Ferrans CE. Quality of life after coronary angioplasty. *Heart Lung* 1993;22:193–199.
 79. McKenna KT, McEniery PT, Maas F, Aroney CN, Bett JH, Cameron J, Holt G, Hossack KF. Percutaneous transluminal coronary angioplasty: Clinical and quality of life outcomes one year later. *Aust N Z J Med* 1994;24:15–21.
 80. Permanyer-Miralda G, Alonso J, Brotons C, Cascant P, Ribera A, Moral I, Romero B, Domingo E, Anto JM, Soler-Soler J. Perceived health over 3 years after percutaneous coronary balloon angioplasty. *J Clin Epidemiol* 1999;52:615–623.
 81. Seto TB, Taira DA, Berezin R, Chauhan MS, Cutlip DE, Ho KK, Kuntz RE, Cohen DJ. Percutaneous coronary revascularization in elderly patients: Impact on functional status and quality of life. *Ann Intern Med* 2000;132:955–958.
 82. Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. *Circulation* 2004;110:3789–3794.
 83. Lowe HC, Oesterle SN, He KL, Macneill BD, Burkhoff D. Outcomes following percutaneous coronary intervention in patients previously considered “without option”: A subgroup analysis of the PACIFIC Trial. *J Intervent Cardiol* 2004;17:87–91.
 84. Wong MS, Chair SY. Changes in health-related quality of life following percutaneous coronary intervention: A longitudinal study. *Int J Nurs Stud* 2007;44:1334–1342.
 85. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia’s approach to chronic total occlusion recanalization (FACTOR) trial. *Circ Cardiovasc Qual Outcomes* 2010;3:284–290.
 86. Melberg T, Nordrehaug JE, Nilsen DW. A comparison of the health status after percutaneous coronary intervention at a hospital with and without on-site cardiac surgical backup: A randomized trial in nonemergent patients. *Euro J Cardiovasc Prevent Rehab* 2010;17:235–243.
 87. de Quadros AS, Lima TC, Rodrigues AP, Modkovski TB, Welter DI, Sarmiento-Leite R, Gottschall CA. Quality of life and health status after percutaneous coronary intervention in stable angina patients: Results from the real-world practice. *Cathet Cardiovasc Intervent* 2011;77:954–960.
 88. Borkon AM, Muehlebach GF, House J, Marso SP, Spertus JA. A comparison of the recovery of health status after percutaneous coronary intervention and coronary artery bypass. *Ann Thorac Surg* 2002;74:1526–1530.
 89. Kattainen E, Sintonen H, Kettunen R, Merilainen P. Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients: 1-year follow-up. *Int J Technol Assess Health Care* 2005; 21:172–179.
 90. Loponen P, Luther M, Korpilahti K, Wistbacka JO, Huhtala H, Laurikka J, Tarkka MR. HRQoL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. *Scand Cardiovasc J* 2009;43:94–99.
 91. van Domburg RT, Daemen J, Morice MC, de Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, van Es GA, Wittebols K, Macours N, Stoll HP, Serruys PW. Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. *EuroIntervention* 2010;5:962–967.
 92. Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA.

Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.

Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

- Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the bypass angioplasty revascularization investigation 2 diabetes trial. *Circulation* 2010; 122:1690–1699.
93. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: Outcomes for patients with double-vessel versus single-vessel coronary artery disease in a veterans affairs cooperative randomized trial. *J Am Coll Cardiol* 1997;29:1505–1511.
 94. Favarato ME, Hueb W, Boden WE, Lopes N, Nogueira CR, Takiuti M, Gois AF, Borges JC, Favarato D, Aldrighi JM, Oliveira SA, Ramires JA. Quality of life in patients with symptomatic multivessel coronary artery disease: A comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. *Int J Cardiol* 2007;116:364–370.
 95. Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. *Circ Cardiovasc Qual Outcomes* 2011;4:172–182.
 96. Wahrborg P. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the coronary angioplasty versus bypass revascularization investigation (CABRI) trial. *Eur Heart J* 1999;20:653–658.
 97. Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: One-year results from the Stent or Surgery trial. *Circulation* 2003;108:1694–1700.
 98. Thiele H, Neumann-Schriedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, Schuler G, Falk V. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. *J Am Coll Cardiol* 2009;53:2324–2331.
 99. Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *N Engl J Med* 2011;364:1016–1026.
 100. Mark DB, Pan W, Clapp-Channing NE, Anstrom KJ, Ross JR, Fox RS, Devlin GP, Martin CE, Adlbrecht C, Cowper PA, Ray LD, Cohen EA, Lamas GA, Hochman JS. Quality of life after late invasive therapy for occluded arteries. *N Engl J Med* 2009;360:774–783.
 101. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. *Heart* 2002;87:140–145.
 102. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. *Circulation* 2004;110:1960–1966.
 103. Krumholz HM, McHorney CA, Clark L, Levesque M, Baim DS, Goldman L. Changes in health after elective percutaneous coronary revascularization. A comparison of generic and specific measures. *Med Care* 1996;34:754–759.
 104. Kahler J, Lutke M, Weckmuller J, Koster R, Meinertz T, Hamm CW. Coronary angioplasty in octogenarians. Quality of life and costs. *Eur Heart J* 1999;20:1791–1798.
 105. Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: A randomized trial. *Circulation* 2004;109:1371–1378.
 106. TIME I. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): A randomised trial. *Lancet* 2001;358:951–957.
 107. McKenna KT, McEniery PT, Maas F, Aroney CN, Bett JH, Cameron J, Garrahy P, Holt G, Hossack KF, Murphy AL. Clinical results and quality of life after percutaneous transluminal coronary angioplasty: A preliminary report. *Cathet Cardiovasc Diagn* 1992;27:89–94.
 108. Little T, Milner MR, Lee K, Constantine J, Pichard AD, Lindsay J Jr. Late outcome and quality of life following percutaneous transluminal coronary angioplasty in octogenarians. *Cathet Cardiovasc Diagn* 1993;29:261–266.
 109. Papadantonaki A, Stotts NA, Paul SM. Comparison of quality of life before and after coronary artery bypass surgery and percutaneous transluminal angioplasty. *Heart Lung* 1994;23:45–52.
 110. Faris JA, Stotts NA. The effect of percutaneous transluminal coronary angioplasty on quality of life. *Prog Cardiovasc Nurs* 1990;5:132–140.
 111. Jorgensen B, Simonsen S, Forfang K, Endresen K, Thaulow E. Effect of percutaneous transluminal coronary angioplasty on exercise in patients with and without previous myocardial infarction. *Am J Cardiol* 1998;82:1030–1033.
 112. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. *Qual Life Res* 2005;14:285–295.
 113. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503–1516.
 114. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DA; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. *J Am Coll Cardiol* 2003;42:1161–1170.
 115. Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss M, Slater J, Frye RL. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. *Circulation* 2011;123:1492–1500.
 116. Graham MM, Norris CM, Galbraith PD, Knudtson ML, Ghali WA, APPROACH I. Quality of life after coronary revascularization in the elderly. *Eur Heart J* 2006;27:1690–1698.
 117. Norris CM, Saunders LD, Ghali WA, Brant R, Galbraith PD, Graham M, Faris P, Dzavik V, Knudtson ML, APPROACH I. Health-related quality of life outcomes of patients with coronary artery disease treated with cardiac surgery, percutaneous coronary intervention or medical management. *Can J Cardiol* 2004;20:1259–1266.
 118. Lukkariinen H, Hentinen M. Treatments of coronary artery disease improve quality of life in the long term. *Nurs Res* 2006;55:26–33.
 119. Benzer W, Hofer S, Oldridge NB. Health-related quality of life in patients with coronary artery disease after different treatments for angina in routine clinical practice. *Herz* 2003;28:421–428.
 120. Wijeyesundera HC, Nallamothu BK, Krumholz HM, Tu JV, Ko DT. Meta-analysis: Effects of percutaneous coronary catheterization and Cardiovascular Interventions DOI 10.1002/ccd.

16 Blankenship et al.

- intervention versus medical therapy on angina relief. *Ann Intern Med* 2010;152:370–379.
121. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of chronic stable angina patients 4 years after coronary angioplasty or coronary artery bypass surgery. *J Intern Med* 2001;249:47–57.
 122. Lukkariinen H, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among women with coronary artery disease. *Heart Lung* 1998;27:189–199.
 123. Hofer S, Doering S, Rumpold G, Oldridge N, Benzer W. Determinants of health-related quality of life in patients with coronary artery disease. *Eur J Cardiovasc Prevent Rehab* 2006;13:398–406.
 124. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. *N Engl J Med* 1997;336:92–99.
 125. Federspiel JJ, Stearns SC, van Domburg RT, Sheridan BC, Lund JL, Serruys PW. Risk-benefit trade-offs in revascularisation choices. *EuroIntervention* 2011;6:936–941.
 126. Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, Sethi G, Morrison DA; Department of Veterans Affairs Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. *J Am Coll Cardiol* 2003;41:1732–1738.
 127. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. *N Engl J Med* 1997;336:92–99.
 128. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;373:1190–1197.
 129. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. Systematic review: The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. *Ann Intern Med* 2007;147:703–716.
 130. Szygula-Jurkewicz B, Wilczek K, Gorzkowska A, Niklewski T, Zembala M, Polonski L. 12-month outcomes of percutaneous and surgical revascularization in acute coronary syndromes without ST-segment elevation in patients with multivessel coronary artery disease. *Pol Arch Med Wewn* 2005;113:56–62.
 131. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. *JAMA* 1997;277:715–721.
 132. Goy JJ, Kaufmann U, Goy-Eggenberger D, Garachemani A, Hurni M, Carrel T, Gaspardone A, Burnand B, Meier B, Versaci F, Tomai F, Bertel O, Pieper M, de Benedictis M, Eeckhout E. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: The SIMA trial. Stenting vs Internal Mammary Artery. *Mayo Clin Proc* 2000;75:1116–1123.
 133. Rittger H, Rieber J, Kogler K, Sinha A, Schmidt M, Breithardt OA, Biggar P, Einsle F, Diegeler A, Brachmann J. Clinical outcome and quality of life after interventional treatment of left main disease with drug-eluting-stents in comparison to CABG in elderly and younger patients. *Clin Res Cardiol* 2011;100:439–446.
 134. Cameron J, Mahanonda N, Aroney C, Hayes J, McEniery P, Gardner M, Bett N. Outcome five years after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting for significant narrowing limited to the left anterior descending coronary artery. *Am J Cardiol* 1994;74:544–549.
 135. Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino V. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol* 2004;93:404–409.
 136. Mortensen OS, Bjorner JB, Newman B, Oldenburg B, Groenvold M, Madsen JK, Andersen HR, DANAMI-2 Study G. Gender differences in health-related quality of life following ST-elevation myocardial infarction: Women and men do not benefit from primary percutaneous coronary intervention to the same degree. *Eur J Cardiovasc Prevent Rehab* 2007;14:37–43.
 137. Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, Cohen HA, Williams DO, Kelsey SF, Detre KM, NHLBI Dynamic Registry Investigators. Angina 1 year after percutaneous coronary intervention: A report from the NHLBI Dynamic Registry. *Am Heart J* 2002;144:826–833.
 138. Ladwig KH, Muhlberger N, Walter H, Schumacher K, Popp K, Holle R, Zitzmann-Roth E, Schomig A. Gender differences in emotional disability and negative health perception in cardiac patients 6 months after stent implantation. *J Psychosom Res* 2000;48:501–508.
 139. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher P. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: One-year results of the randomized TIME trial. *JAMA* 2003;289:1117–1123.
 140. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: Four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). *Circulation* 2004;110:1213–1218.
 141. Chait R, Zad O, Ramineni R, Shukla A, Mitchell A. Midterm outcomes and quality of life following percutaneous coronary intervention in nonagenarians. *Am J Cardiol* 2011;107:1609–1612.
 142. Bundhoo SS, Kalla M, Anantharaman R, Morris K, Chase A, Smith D, Anderson RA, Kinnaird TD. Outcomes following PCI in patients with previous CABG: A multi centre experience. *Cathet Cardiovasc Intervent* 2011;78:169–176.
 143. Hawkes AL, Mortensen OS. Up to one third of individual cardiac patients have a decline in quality of life post-intervention. *Scand Cardiovasc J* 2006;40:214–218.
 144. Taira DA, Seto TB, Ho KK, Krumholz HM, Cutlip DE, Berezin R, Kuntz RE, Cohen DJ. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. *Circulation* 2000;102:1369–1374.
 145. Bourassa MG, Brooks MM, Mark DB, Trudel J, Detre KM, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Smith HC, Whitlow PL, Wiens RD, Hlatky MA. Quality of life after coronary revascularization in the United States and Canada. *Am J Cardiol* 2000;85:548–553.

146. Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: The ETICA trial. *J Am Coll Cardiol* 2001;37:1891–1900.
147. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). *Patient Ed Counsel* 2001;43:219–230.
148. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of chronic stable angina patients 4 years after coronary angioplasty or coronary artery bypass surgery. *J Intern Med* 2001;249:47–57.
149. Jamieson M, Wilcox S, Webster W, Blackhurst D, Valois RF, Durstine JL. Factors influencing health-related quality of life in cardiac rehabilitation patients. *Prog Cardiovasc Nurs* 2002;17:124–131.
150. Haddock CK, Poston WS, Taylor JE, Conard M, Spertus J. Smoking and health outcomes after percutaneous coronary intervention. *Am Heart J* 2003;145:652–657.
151. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. *Circulation* 2004;110:1960–1966.
152. Spertus JA, Nerella R, Kettlekamp R, House J, Marso S, Borikon AM, Rumsfeld JS. Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. *Circulation* 2005;111:768–773.
153. Denvir MA, Lee AJ, Rysdale J, Walker A, Eteiba H, Starkey IR, Pell JP. Influence of socioeconomic status on clinical outcomes and quality of life after percutaneous coronary intervention. *J Epidemiol Community Health* 2006;60:1085–1088.
154. Leslie SJ, Rysdale J, Lee AJ, Eteiba H, Starkey IR, Pell J, Denvir MA. Unemployment and deprivation are associated with a poorer outcome following percutaneous coronary angioplasty. *Int J Cardiol* 2007;122:168–169.
155. Kriston L, Gunzler C, Agyemang A, Bengel J, Berner MM, SPARK Study G. Effect of sexual function on health-related quality of life mediated by depressive symptoms in cardiac rehabilitation. findings of the SPARK project in 493 patients. *J Sex Med* 2010;7:2044–2055.
156. Rittger H, Rieber J, Kogler K, Sinha A, Schmidt M, Breithardt OA, Biggar P, Einsle F, Diegeler A, Brachmann J. Clinical outcome and quality of life after interventional treatment of left main disease with drug-eluting-stents in comparison to CABG in elderly and younger patients. *Clin Res Cardiol* 2011;100:439–446.
157. Simoons ML, Windecker S. Controversies in cardiovascular medicine: Chronic stable coronary artery disease: Drugs vs. revascularization. *Eur Heart J* 2010;31:530–541.
158. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. *Am Heart J* 2003;145:36–41.
159. Skaggs BG, Yates BC. Quality of life comparisons after coronary angioplasty and coronary artery bypass graft surgery. *Heart Lung* 1999;28:409–417.
160. Groeneveld PW, Suh JJ, Matta MA. The costs and quality-of-life outcomes of drug-eluting coronary stents: A systematic review. *J Interv Cardiol* 2007;20:1–9.
161. Ploegmakers MM, Viscaal AM, Finch L, Mayo NE, Brophy JM. The disutility of restenosis—the impact of repeat percutaneous coronary intervention on quality of life. *Can J Cardiol* 2010;26:197–200.
162. Jamieson M, Wilcox S, Webster W, Blackhurst D, Valois RF, Durstine JL. Factors influencing health-related quality of life in cardiac rehabilitation patients. *Prog Cardiovasc Nurs* 2002;17:124–131.
163. El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. *J Urol* 2004;172:251–254.
164. Lukkariinen H, Lukkariinen O. Sexual satisfaction among patients after coronary bypass surgery or percutaneous transluminal angioplasty: Eight-year follow-up. *Heart Lung* 2007;36:262–269.
165. Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, Foster E, Jaarsma T, Kloner RA, Lange RA, Lindau ST, Maron BJ, Moser DK, Ohman EM, Seftel AD, Stewart WJ. Sexual activity and cardiovascular disease: A scientific statement from the American Heart Association. *Circulation* 2012;125:1058–1072.
166. Beauchamp TL, Childress JF. *Principles of Biomedical Ethics*. Oxford University Press; 1989.
167. Paterick TJ, Carson GV, Allen MC, Paterick TE. Medical informed consent: General considerations for physicians. *Mayo Clin Proc* 2008;83:313–319.
168. Critchfield TS, Kollins SH. Temporal discounting: Basic research and the analysis of socially important behavior. *J Appl Behav Anal* 2001;34:101–122.
169. Holmboe ES, Fiellin DA, Cusanelli E, Remetz M, Krumholz HM. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. *J Gen Intern Med* 2000;15:632–637.
170. Feinstein AR. The “chagrin factor” and qualitative decision analysis. *Arch Intern Med* 1985;145:1257–1259.